Is the current genetics and insurance moratorium an effective long term regulatory solution for Australia?
Genetic discrimination in life insurance is a longstanding issue in Australia,1,2 and has been the subject of two government inquiries.3,4 The use of genetic test results in underwriting continues to be self‐regulated by the life insurance industry.5 In 2019, following Parliamentary Joint Committee recommendations,4 the industry voluntarily introduced a moratorium restricting the use of genetic test results in life insurance underwriting for polices worth up to AU$500 000. Although the moratorium is an important step, concerns remain around the financial limits, public awareness, lack of government oversight and compliance monitoring. The impact and effectiveness of the moratorium needs evaluation to inform the planned 2022 review. A new research project has been funded by the Australian Government’s Genomic Health Futures Mission to serve that important function.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Tiller J, Otlowski M, Lacaze P. Should Australia ban the use of genetic test results in life insurance? Front Public Health 2017; 5: 330.
- 2. Otlowski M, Tiller J, Barlow‐Stewart K, Lacaze P. Genetic testing and insurance in Australia. Aust J Gen Pract 2019; 48: 96–99.
- 3. Australian Law Reform Commission. Essentially yours: the protection of human genetic information in Australia. Sydney: ALRC, 2003. http://www.alrc.gov.au/publications/report-96 (viewed June 2020).
- 4. Parliamentary Joint Committee on Corporations and Financial Services. Report: life insurance industry. Canberra: Commonwealth of Australia, 2018. https://www.aph.gov.au/Parliamentary_Business/Committees/Joint/Corporations_and_Financial_Services/LifeInsurance/Report (viewed June 2020).
- 5. Newson AJ, Tiller J, Keogh LA, et al. Genetics and insurance in Australia: concerns around a self‐regulated industry. Public Health Genomics 2017; 20: 247–256.
- 6. Commonwealth Department of Health; Australian Health Ministers’ Advisory Council. National Health Genomics Policy Framework and Implementation Plan 2018–2021. Canberra: Commonwealth of Australia, 2017. https://www1.health.gov.au/internet/main/publishing.nsf/Content/national-health-genomics-policy-framework-2018-2021 (viewed July 2020).
- 7. Rothstein MA. Time to end the use of genetic test results in life insurance underwriting. J Law Med Ethics 2018; 46: 794–801.
- 8. Keogh LA, Niven H, Rutstein A, et al. Choosing not to undergo predictive genetic testing for hereditary colorectal cancer syndromes: expanding our understanding of decliners and declining. J Behav Med 2017; 1–12.
- 9. Otlowski M, Taylor S, Bombard Y. Genetic discrimination: international perspectives. Annu Rev Genomics Hum Genet 2012; 13: 433–454.
- 10. Financial Services Council. FSC Standard No. 11: Moratorium on Genetic Tests in Life Insurance. Sydney: FSC, 2019. https://www.fsc.org.au/resources-category/standard/1779-standard-11-moratorium-on-genetic-tests-in-life-insurance/file (viewed July 2020).
- 11. Millward M, Tiller J, Bogwitz M, et al. Impact of direct‐to-consumer genetic testing on Australian clinical genetics services. Eur J Med Genet 2020; 63: 103968.
- 12. HM Government and Association of British Insurers. Code on Genetic Testing and Insurance. UK: HM Government and ABI, 2018. https://www.abi.org.uk/globalassets/files/publications/public/genetics/code-on-genetic-testing-and-insurance-final.pdf (viewed July 2020).
- 13. Hon Greg Hunt MP. Over $33 million to boost genomics research into cancers and to combat children’s diseases [media release]. 6 May 2020. https://www.health.gov.au/ministers/the-hon-greg-hunt-mp/media/over-33-million-to-boost-genomics-research-into-cancers-and-to-combat-childrens-diseases (viewed June 2020).
- 14. Tiller J, Keogh L, Wake S, et al. Genetics, insurance and professional practice: survey of the Australasian clinical genetics workforce. Front Public Health 2018; 6: 333.
- 15. Tiller J, Morris S, Rice T, et al. Genetic discrimination by Australian insurance companies: a survey of consumer experiences. Eur J Hum Genet 2019; 28: 108–113.
We are members of the A‐GLIMMER project team. A‐GLIMMER is funded by the first competitive round of the Genomic Health Futures Mission, part of the Australian Government’s Medical Research Future Fund (grant no. 76721). We thank the other members of the A-GLIMMER investigative team — Aideen McInerney-Leo, Louise Keogh, Andrea Belcher, Tiffany Boughtwood, Kristine Barlow-Stewart and Martin Delatycki — for their crucial and ongoing contribution to the project. We would also like to thank our project partners — consumer groups, research studies, clinical services, and industry groups — for their ongoing support.
No relevant disclosures.